NCT04046432 (Vigiis101) is a NA clinical trial of Vigiis 101-LAB in Gastrointestinal Microbiome, sponsored by SunWay Biotech Co., LTD..

Who is sponsoring NCT04046432?

NCT04046432 is sponsored by SunWay Biotech Co., LTD..

What drugs are being tested in NCT04046432?

Interventions in NCT04046432: Vigiis 101-LAB, Placebo.

What condition does NCT04046432 study?

NCT04046432 studies Gastrointestinal Microbiome.

Is NCT04046432 still recruiting?

NCT04046432 is currently completed. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT04046432: Vigiis101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity

Completed NA Last updated 7 August 2019

What this trial tests

NA trial testing Vigiis 101-LAB in Gastrointestinal Microbiome in 54 participants. Completed in 20 March 2018.

Timeline

27 March 2017

Primary endpoint
22 December 2017

20 March 2018

Quick facts

Lead sponsor	SunWay Biotech Co., LTD.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	basic science
Enrollment	54
Start date	27 March 2017
Primary completion	22 December 2017
Estimated completion	20 March 2018
Sites	1 location across Taiwan

Drugs / interventions tested

Vigiis 101-LAB
Placebo

Conditions studied

Gastrointestinal Microbiome — all drugs for Gastrointestinal Microbiome →

Sponsor

SunWay Biotech Co., LTD.

Who can join

Adults 20 to 65, any sex, with Gastrointestinal Microbiome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vigiis 101-LAB capsules I and II are produced from the fermentation of Lactobacillus paracasei subsp. paracasei NTU 101. Investigators have examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day, respectively) on gut microflora in clinical trial 1, and on peristalsis, related immunity, and anti-oxidative capacity in clinical trial 2, during a 4-week randomized, double-blind, placebo-controlled, adaptive-design study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study.
Chen CL, Liou JM, Lu TM, Lin YH, et al · · 2020 · cited 10× · PMID 32995642 · DOI 10.1016/j.heliyon.2020.e04979

Verify or expand the search:

Other trials of Vigiis 101-LAB

Trials testing the same drug.

NCT04088474 — Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora · NA · completed

Other recruiting trials for Gastrointestinal Microbiome

Currently open trials in the same condition.

NCT06802276 — Smart Underwear to Measure Diet-Induced Hydrogen Sulfide Production · NA · recruiting
NCT06207136 — Microbiome and Diet in Parkinson's Disease · NA · recruiting
NCT06359808 — Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis · recruiting
NCT05692024 — COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER · Phase 1, PHASE2 · recruiting
NCT05961189 — Influence of Short-Term Antibiotic Therapy on Exercise · EARLY_PHASE1 · recruiting

Other SunWay Biotech Co., LTD. trials

Trials by the same sponsor.

NCT06968299 — Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological · NA · recruiting
NCT05869799 — Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants · NA · unknown
NCT05737342 — Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose · NA · recruiting
NCT05737355 — Effect of ANKASCIN 568-P Products Regulating Blood Lipid · NA · recruiting
NCT05719649 — The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04046432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SunWay Biotech Co., LTD.
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04046432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing